BCM
CRSP icon

Brasada Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Brasada Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,685
Closed -$717K – 156
2020
Q4 		$717K Buy
+4,685
New +$554K 0.16% 102

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Brasada Capital Management's CRSP Position: Q1 2021 in Review

Brasada Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 4,685 shares — an estimated $717K sold.

Brasada Capital Management first reported a position in CRSP in Q4 2020 and held it in 1 quarter. The position peaked at $717K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • Brasada Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Brasada Capital Management sold 4,685 CRISPR Therapeutics shares in Q1 2021, an estimated $717K.
  • Brasada Capital Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 1 quarter.
  • Brasada Capital Management's CRISPR Therapeutics position peaked at $717K in Q4 2020.
  • 443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on Brasada Capital Management's 13F filing for Q1 2021, filed 7 May 2021.